Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States.
J Med Chem. 2010 Dec 9;53(23):8368-75. doi: 10.1021/jm100825h. Epub 2010 Nov 9.
A new series of 3-ethynyl-1H-indazoles has been synthesized and evaluated in both biochemical and cell-based assays as potential kinase inhibitors. Interestingly, a selected group of compounds identified from this series exhibited low micromolar inhibition against critical components of the PI3K pathway, targeting PI3K, PDK1, and mTOR kinases. A combination of computational modeling and structure-activity relationship studies reveals a possible novel mode for PI3K inhibition, resulting in a PI3Kα isoform-specific compound. Hence, by targeting the most oncogenic mutant isoform of PI3K, the compound displays antiproliferative activity both in monolayer human cancer cell cultures and in three-dimensional tumor models. Because of its favorable physicochemical, in vitro ADME and drug-like properties, we propose that this novel ATP mimetic scaffold could prove useful in deriving novel selecting and multikinase inhibitors for clinical use.
已经合成了一系列新的 3-炔基-1H-吲唑,并在生化和基于细胞的测定中进行了评估,作为潜在的激酶抑制剂。有趣的是,从该系列中鉴定出的一组选定的化合物对 PI3K 途径的关键成分表现出低微摩尔抑制作用,针对 PI3K、PDK1 和 mTOR 激酶。计算建模和构效关系研究的结合揭示了一种可能的新型 PI3K 抑制模式,导致 PI3Kα 同工型特异性化合物。因此,通过针对 PI3K 的最致癌突变同工型,该化合物在单层人癌细胞培养物和三维肿瘤模型中均显示出抗增殖活性。由于其有利的物理化学、体外 ADME 和类药性特性,我们提出该新型 ATP 模拟物支架可能有助于为临床用途开发新型选择性和多激酶抑制剂。